Saturday, November 14, 2026

Dollar Plunges to 2022 Lows as Euro Gains 14%, Triggering Global Currency Realignment

The US dollar hit its weakest level since 2022 against major currencies, with the euro surging 14% and the pound advancing 7% in 2025. Federal Reserve leadership transition uncertainty and geopolitical shifts are driving the global forex upheaval, while emerging markets face severe volatility.

ViaNews Editorial Team

February 23, 2026

From our archive, published before source-traceability. How we work

Source Trace Score3 source documents3 with a live linkVerifiability: Strong
Dollar Plunges to 2022 Lows as Euro Gains 14%, Triggering Global Currency Realignment
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

The US dollar fell to its lowest level since 2022 against major currencies, with the euro gaining 14% and the British pound advancing 7% in 2025—a currency realignment reshaping global trade and investment flows.

The pound traded at $1.3086, down 0.5% from recent highs, and fell 0.4% to €1.13—its lowest since April 2023. Jordan Rochester at Mizuho Bank projects sterling could break below $1.30 in coming months despite year-to-date gains.

Federal Reserve leadership uncertainty is weakening dollar positioning ahead of Jerome Powell's replacement in June 2026. Progress on Iran-US nuclear negotiations has added to currency volatility, while shifting central bank policies favor euro-area and UK assets over dollar holdings.

Emerging markets absorbed sharp losses. Turkey's lira plunged 17% after a carry trade collapse forced rapid unwinding of leveraged positions. Safe-haven flows pushed investors toward the Swiss franc as forex turbulence spread across developing economies.

UK gilt yields climbed to multi-decade highs, with 30-year bonds reaching 5.21%—the highest since 1998. An inflation-linked bond auction drew £69 billion in bids for £4.25 billion of debt, surpassing March's £67.5 billion record. About 25% of UK gilts are tied to inflation versus 10% in the US and France, making sterling particularly sensitive to inflation expectations.

European equity markets outperformed US indices as currency movements boosted export competitiveness. The Stoxx 600 rose 0.6% to a record 583.4 points, while France's CAC 40 gained 0.7% and Germany's DAX advanced 0.9%.

Traders are positioning for continued dollar weakness through the June 2026 Fed transition. Currency analysts are focusing on EUR/USD, GBP/USD, and emerging market pairs vulnerable to further carry trade unwinds.

Gold traded above $4,100 per ounce on dollar weakness and safe-haven demand. WTI crude rose 1.5% to around $61 per barrel as currency shifts reshaped commodity markets globally.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score3 source documents3 with a live linkVerifiability: Strong
  1. [1]News articleUk· November 12, 2025
    Pound hits two-year low against euro as Starmer under fire
  2. [2]News articleYahoo Finance· December 31, 2025
    Stock market today: Dow, S&P 500, Nasdaq post double-digit gains in 2025 as AI trade powers market once again
  3. [3]News articleYahoo Finance· February 17, 2026
    Stock market today: Dow, S&P 500, Nasdaq waver in volatile trading as AI anxiety lingers

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com